Reviewing, indicating, and counting books for modern research evaluation systems

In this chapter, we focus on the specialists who have helped to improve the conditions for book assessments in research evaluation exercises, with empirically based data and insights supporting their greater integration. Our review highlights the research carried out by four types of expert communities, referred to as the monitors, the subject classifiers, the indexers and the indicator constructionists. Many challenges lie ahead for scholars affiliated with these communities, particularly the latter three. By acknowledging their unique, yet interrelated roles, we show where the greatest potential is for both quantitative and qualitative indicator advancements in book-inclusive evaluation systems.Comment: Forthcoming in Glanzel, W., Moed, H.F., Schmoch U., Thelwall, M. (2018). Springer Handbook of Science and Technology Indicators. Springer Some corrections made in subsection 'Publisher prestige or quality

Big Data for the Greater Good: An Introduction

Big Data, perceived as one of the breakthrough technological developments of our times, has the potential to revolutionize essentially any area of knowledge and impact on any aspect of our life. Using advanced analytics techniques such as text analytics, machine learning, predictive analytics, data mining, statistics, and natural language processing, analysts, researchers, and business users can analyze previously inaccessible or unusable data to gain new insights resulting in better and faster decisions, and producing both economic and social value; it can have an impact on employment growth, productivity, the development of new products and services, traffic management, spread of viral outbreaks, and so on. But great opportunities also bring great challenges, such as the loss of individual privacy. In this chapter, we aim to provide an introduction into what Big Data is and an overview of the social value that can be extracted from it; to this aim, we explore some of the key literature on the subject. We also call attention to the potential ‘dark’ side of Big Data, but argue that more studies are needed to fully understand the downside of it. We conclude this chapter with some final reflections

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

'Knowledge workers' as the new apprentices: the influence of organisational autonomy, goals and values on the nurturing of expertise

This paper explores the concept of apprenticeship in the context of the professional formation of knowledge workers. It draws on evidence from research conducted in two knowledge intensive organizations: a research-intensive, elite university; and a ‘cutting edge’ software engineering company. In the former, we investigated the learning environments of contract researchers, whilst in the latter we focused on the learning environments of software engineers. Both organisations have ‘global’ reach in that they operate within international marketplaces and see themselves as international players. The research in the university and the software engineering company was conducted as part of a larger project that investigated work and learning across diverse public and private occupational sectors (Felstead et al 2009). The research evidence about the workplace learning and career formation experiences of these knowledge workers is explored using aspects of the expansive – restrictive framework to compare the environments in terms of three themes: organisational goals and workforce development; expertise and trust; and, opportunities to expand learning. The paper argues that conceiving the professional formation of knowledge workers as apprenticeship provides an approach which can improve the way employers construct and support that formation

Socialist Life of a U.S. Army Computer in the GDR’s Financial Sector

Part 4: CoCom and ComeconInternational audienceThis article investigates the role of the first digital computer in GDR’s socialist financial system. Why did the GDR’s Ministry of Finance import a Univac computer from the U.S. army in 1965, even though the country aimed at computational autarky and was restricted by embargo? The main argument is that the Ministry of Finance imported the computer to kickstart its program for electronic data processing. They succeeded because they not only imported a machine, but also reframed it ideologically. They drew on the notion of the computer as a universal machine and adapted it to local conditions. The process hints to the ambiguity of the later decision of the East Bloc toward copying IBM’s system architecture. This article investigates this process by following the traces of an early computer and the ideas surrounding it through the Iron Curtain. It stresses the role of early computer users with the example of GDR’s financial system in contrast to better known producer stories. Through the analysis of exclusive material, this is suggesting a different perspective on the import procedures of Eastern European countries in the Cold War. A policy change in the Cold War towards détente becomes visible as early as in 1965